Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19.
Saved in:
| Title: | Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. |
|---|---|
| Authors: | Jones RS; Eli Lilly and Company, Indianapolis, IN, USA., Smith PS; Eli Lilly and Company, Indianapolis, IN, USA., Berg PH; Eli Lilly and Company, Indianapolis, IN, USA., de la Peña A; Eli Lilly and Company, Indianapolis, IN, USA., Cook PP; East Carolina University Brody School of Medicine, Greenville, NC, USA., Shawa I; Franciscan Alliance, Indianapolis, IN, USA., Kioussopoulos KM; Franciscan Alliance, Indianapolis, IN, USA., Hu Y; Eli Lilly and Company, Indianapolis, IN, USA., Schott RJ; Eli Lilly and Company, Indianapolis, IN, USA. |
| Source: | Clinical medicine insights. Circulatory, respiratory and pulmonary medicine [Clin Med Insights Circ Respir Pulm Med] 2022 Aug 10; Vol. 16, pp. 11795484221119316. Date of Electronic Publication: 2022 Aug 10 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: United States NLM ID: 101537753 Publication Model: eCollection Cited Medium: Print ISSN: 1179-5484 (Print) Linking ISSN: 11795484 NLM ISO Abbreviation: Clin Med Insights Circ Respir Pulm Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-5484 |
|---|---|
| DOI: | 10.1177/11795484221119316 |
